Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome
Information source: New York University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Brugada Syndrome; Arrhythmogenic Right Ventricular Cardiomyopathy
Intervention: flecainide iv (Drug)
Phase: Phase 1/Phase 2
Status: Enrolling by invitation
Sponsored by: New York University School of Medicine Official(s) and/or principal investigator(s): Silvia Priori, MD, PhD, Principal Investigator, Affiliation: NYU School of Medicine
Summary
The study aims to use flecainide infusion test as diagnostic test to unmask concealed
Brugada Syndrome cases. It proposes to assess the safety profile of this test in US patients
and its higher sensitivity when compared to procainamide infusion (the conventional drug
used in the USA). As a substudy it proposes to apply this test to early ARVC cases in order
to evaluate if ECG changes similar to those seen in Brugada Syndrome could be unmasked by
flecainide iv.
Clinical Details
Official title: DIAGNOSTIC VALUE AND SAFETY OF FLECAINIDE INFUSION TEST IN BRUGADA SYNDROME
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Primary outcome: diagnosis
Secondary outcome: safety: absence of arrhythmias elicited during the test
Detailed description:
Brugada Syndrome is an inherited arrhythmogenic disease responsible for life-threatening
arrhythmias and sudden cardiac death in young individuals with structural normal heart.
It is characterized by a peculiar ECG pattern, but this pattern could be intermittent. The
infusion of sodium channel blockers (flecainide, ajmaline, procainamide) is used to unmask
a concealed ECG pattern, thus providing an essential contribution to the diagnosis of this
condition.
In the current clinical practice in USA, only procainamide is used for diagnostic purposes;
however in Europe only ajmaline and flecainide, available as iv formulations, are widely
used. European and Japanese studies have demonstrated that the use of flecainide harbors
less risks of adverse events in patients and may have a higher accuracy in unraveling the
presence of the disease.
In the present study the investigators propose to use flecainide infusion test in the
Cardiovascular Genetics Program at NYUMC, in order to assess its sensitivity and specificity
in diagnosing the disease and compare the incidence of adverse events to that observed
during procainamide use.
Additionally, the investigators propose to extend the study protocol to patients with a
suspect diagnosis of Arrhythmogenic Right Ventricular Tachycardia (ARVC), due to the
possible overlap between the two conditions.
The study has the following aims:
1. To demonstrate the higher sensitivity and specificity of flecainide iv infusion
compared to procainamide infusion for the diagnosis of Brugada Syndrome.
2. To demonstrate that flecainide is equally safe or safer than procainamide to use for
diagnosing Brugada Syndrome.
3. To demonstrate that flecainide has high sensitivity and specificity in diagnosing also
some patients with early stage Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Suspect diagnosis of Brugada Syndrome or ARVC
- Idiopathic ventricular fibrillation and suspect concealed Brugada syndrome
- Family history of Brugada Syndrome
- Family history of unexpected cardiac sudden death
Exclusion Criteria:
- Type 1 Brugada Syndrome ECG
- Pregnancy
- History and/or evidence of ischemic cardiomyopathy
- Recent myocardial infarction
- Allergy or known adverse reaction to flecainide
Locations and Contacts
Additional Information
Starting date: July 2010
Last updated: November 25, 2014
|